What Syvento BioTech does

SyVento BioTech (legal entity SyVento Sp. z o.o.) is a Polish biotechnology Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in Skawina, near Kraków. The company specializes in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, serving biotech and pharmaceutical clients developing RNA-based therapeutics, gene therapies, and advanced lipid-formulated drug products. Its offerings span four integrated platforms: a Genetic Platform for end-to-end mRNA synthesis (IVT, TFF purification, oligo(dT) capture, HPLC polishing); a Delivery Platform covering liposomes, LNPs, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and SEDDS; a Manufacturing Platform scaling from 25 µl lab batches to 50 L commercial batches with 2,000–3,000 vials/hour continuous fill-and-finish; and Drug Development Expertise covering analytics, bioassay, CMC, and regulatory support.

The company operates from a state-of-the-art facility with 537 m² of sterile cGMP pharmaceutical production, 541 m² of GLP laboratory space, 646 m² of non-sterile production, and 1,478 m² of warehousing. SyVento obtained its EU GMP Certificate of Compliance on 28 April 2026 (manufacturing authorization no. 285/0662/25) and states it is the only entity in Poland offering this combined CDMO service portfolio for RNA-based therapies and LNPs with injectable manufacturing and fill-and-finish.

SyVento generates revenue through bespoke project-based CDMO contracts and long-term strategic partnerships, targeting both early-stage biotech startups and established pharmaceutical companies. Its 100% PhD-qualified R&D team, PhD-led CTO, and joint development agreement with Molecure (formerly OncoArendi, 2021) and manufacturing partnership with NanoSanguis S.A. (May 2026) anchor its commercial pipeline. Go-to-market is direct enterprise sales via a commercial advisory team and active participation in major industry conferences (BIO, TIDES USA, CDMO Live, CE BioForum, UK Biotech Day, EUROBIOTECH).

Name

Syvento BioTech

Legal name

SyVento Sp. z o.o.

Website

https://syvento.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

SyVento BioTech is a Polish CDMO specializing in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, offering end-to-end mRNA synthesis, LNP formulation, GMP manufacturing, and fill-and-finish services to biotech and pharmaceutical clients developing RNA-based therapeutics.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO services for RNA-based therapeutics and lipid nanoparticle drug delivery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Lipid nanoparticle CDMO
• RNA synthesis services
• Lipid-based drug delivery
• GMP contract manufacturing
• Pharmaceutical development services

Headquarters

HQ city

Skawina

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain

Revenue model

1. CDMO Services (Contract Development & Manufacturing): SyVento operates as a full-service Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early formulation development through GMP manufacturing and fill-and-finish. Revenue is generated through project-based service contracts and long-term CDMO partnerships. Services include RUO/GMP-grade mRNA synthesis, preclinical & clinical drug development, process optimization, scale-up and technology transfer, GMP manufacturing, in-house analytics, bioassay, and regulatory support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Syvento BioTech operates as a biotechnology Contract Development and Manufacturing Organization (CDMO) specializing in lipid-based nanocarriers and Lipid Nanoparticle (LNP) technology for RNA-based therapeutics. The company provides end-to-end services across four integrated platforms: RNA/mRNA synthesis (Genetic Platform), LNP and liposome formulation (Delivery Platform), scale-up and GMP-grade fill-and-finish manufacturing (Manufacturing Platform), and analytical/regulatory drug development support (Drug Development Expertise). Customers include biotech startups and pharmaceutical companies developing lipid-based drug products, RNA-based therapeutics, and gene therapies.

Product overview

Syvento BioTech is a biotechnology CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform of integrated services for lipid-based drug delivery and mRNA technology. The core offering consists of four interconnected platforms: the Genetic Platform (RNA/mRNA synthesis), the Delivery Platform (LNP and liposome formulations), the Manufacturing Platform (scale-up and fill-finish), and Drug Development Expertise (analytical and regulatory services). These platforms work together to provide end-to-end support from early development through commercialization of RNA-based therapeutics and lipid nanoparticle drug products.

Differentiator

Problem solved

Functional benefit

Products and services

• Genetic Platform (RNA Synthesis) End-to-end mRNA synthesis service covering IVT reaction, TFF purification, oligo(dT) capture, Prima S HPLC polishing for dsRNA removal, buffer exchange, and sterile filtration. Produces high-quality mRNA with high purity, flexibility, scalability, time-effectiveness, and repeatability for pre-clinical through commercial supply, for biotech startups and pharmaceutical companies developing mRNA-based drug products.
• Delivery Platform (LNP and Lipid-Based Formulation) Development of lipid-based drug delivery systems including liposomes, LNPs for gene therapies (DNA and RNA), Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), Nanoemulsions, and Self-Emulsifying Drug Delivery Systems (SEDDS). Modular control over particle size, surface charge, and composition; all formulations tested per QbD and ICH guidelines. Targets customers developing RNA-based therapeutics and gene therapies.
• Manufacturing Platform (Scale-up and GMP Fill-and-Finish) Scaling production of lipid nanocarrier formulations from laboratory scale to pilot, demo, and technical scale, including batches up to 50L. Includes GMP-grade continuous vial filling at 2,000–3,000 vials per hour (FnF), isolator technology, lyophilizers, and automated filling equipment. Supports biotech and pharmaceutical customers from lab scale through commercial readiness.
• Drug Development Expertise (Analytical, CMC, and Regulatory Support) End-to-end analytical and development services supporting drug development from early clinical phases to commercialization, including CMC process development, GMP manufacturing, bioassay, in-house analytics, and regulatory support. All formulations tested per QbD and ICH guidelines. Customers are biotech and pharmaceutical partners.
• CDMO Services (Comprehensive End-to-End Contract Development and Manufacturing) Comprehensive Contract Development and Manufacturing Organization services spanning RUO/GMP-grade mRNA synthesis, preclinical and clinical drug development, process optimization, scale-up and technology transfer, GMP manufacturing with fill-and-finish, in-house analytics, bioassay, and regulatory support. Provides end-to-end collaboration from early development through commercial readiness for biotech and pharmaceutical customers.

Quantifiable outcome

• Up to 50L batch scale; 2000–3000 vials per hour continuous fill-and-finish
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• DefenceTech Cluster / Horizon of Security (Horyzont Bezpieczeństwa)minorStrategic or Co-development Partner · 1 June 2026SyVento joined the DefenceTech Cluster / Horizon of Security initiative alongside organizations including Polish Armaments Group (PGZ), IBM Poland, ENEA, AGH University of Kraków, Kielce University of Technology, Starachowice Special Economic Zone, INFOVER, CELiUS, ELIBERTOON, and MOSTOSTAL Kielce. The initiative aims to strengthen Poland's technological resilience, strategic autonomy, and innovation capabilities through cross-sector collaboration, including in dual-use technologies, R&D, and industrial cooperation.
• NanoSanguis S.A.coreStrategic or Co-development Partner · 1 May 2026SyVento provides comprehensive technological and analytical support for the development and manufacturing of NanOX 4 Kidney, a next-generation kidney perfusion fluid based on a synthetic oxygen carrier, as a Class III medical device. SyVento delivers technical support of the manufacturing process, including analytics and production of preclinical and clinical batches.
• Molecure (formerly OncoArendi)coreStrategic or Co-development Partner · 1 January 2021SyVento and OncoArendi (now Molecure) signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02. This collaboration solidified SyVento's reputation in the field of lipid-based drug delivery and RNA therapeutics.
• KymosminorOthersListed as a partner on SyVento's About Us page. Nature of collaboration not detailed in available source material.
• AMM (Alliance for Modern Medicine / mrnamedicines.org)minorOthersListed as a partner on SyVento's About Us page. Nature of collaboration not detailed in available source material.
• BioinMedminorOthersListed as a partner on SyVento's About Us page. BioinMed is a biotech/medtech industry association. Nature of collaboration not detailed in available source material.
• CE BioForumminorOthersListed as a partner on SyVento's About Us page. CE BioForum is a Central European biotech industry platform. Nature of collaboration not detailed in available source material.
• LifeScience Cluster (KlasterLifeScience.pl)minorOthersListed as a partner on SyVento's About Us page. LifeScience Cluster connects biotech, pharma, and academic organizations in Poland. Nature of collaboration not detailed in available source material.
• Jagiellonian University (UJ)coreStrategic or Co-development PartnerAcademic collaboration partner listed on SyVento's About Us page. SyVento pursues academic partnerships for joint research projects on LNP and lipid-based drug delivery, knowledge sharing, access to specialized expertise, grant and funding opportunities, student internships and training, and joint publications.
• University of Wrocław (UWR)coreStrategic or Co-development PartnerAcademic collaboration partner listed on SyVento's About Us page. Dominik Lipka, CTO, earned his PhD at the University of Wrocław's Faculty of Biotechnology, Department of Lipids and Liposomes. SyVento engages in joint research, student internships, and publications with academic institutions.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lonza: Lonza is one of the world's largest CDMOs with dedicated mRNA and lipid nanoparticle capabilities at scale, serving both clinical and commercial supply. It represents the global incumbent against which SyVento will compete for biotech outsourcing contracts.
• Rentschler Biopharma: Rentschler is a German-based CDMO focused on complex biologics including mAb, recombinant protein, and increasingly nucleic-acid-based therapeutics. It is a relevant European regional incumbent with overlapping customer base and GMP capabilities.
• Evonik Health Care: Evonik is a leading supplier of functional excipients and lipids for LNP formulations (including for COVID-19 vaccines) and offers CDMO services for parenteral drug products and complex formulations. It is a broad incumbent in the LNP-lipid value chain SyVento serves.
• Catalent (Novo Holdings): Catalent is a major global CDMO with extensive fill-finish, biologics, and nucleic-acid capabilities, including an mRNA-focused partnership with Moderna. Its breadth and scale make it the broad incumbent reference for SyVento's service portfolio.
• AGC Biologics: AGC Biologics is a global CDMO with cell, gene therapy, and biologics GMP manufacturing including microbial and mammalian platforms. Its integrated CDMO model parallels SyVento's positioning as an end-to-end CDMO partner.

Emerging players

• Acuitas Therapeutics: Acuitas is a Canadian specialist in ionizable cationic lipid and LNP technology for RNA therapeutics (used in Moderna's and Pfizer-BioNTech's COVID vaccines). It is directly comparable to SyVento's Delivery Platform for LNP formulation know-how.
• CureVac: CureVac is a clinical-stage mRNA company with in-house manufacturing capabilities and external CDMO partnerships. It is comparable as a European mRNA/LNP operator, though it remains primarily a therapeutics developer rather than a pure CDMO.
• Genevant Sciences: Genevant develops lipid nanoparticle delivery technology for RNA therapeutics (siRNA, mRNA, gene editing) and licenses its platform plus offers formulation services. Its LNP-centric model overlaps with SyVento's Delivery Platform.

Direct peers

• Aldevron (Danaher): Aldevron is a US-based CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for cell and gene therapies. Its nucleic-acid CDMO offering directly overlaps with SyVento's Genetic Platform and GMP mRNA synthesis service.
• BioNTech IMFS (formerly Polymun Scientific): BioNTech IMFS is the contract manufacturing arm of BioNTech, offering mRNA/LNP CDMO services including GMP-grade mRNA production and LNP encapsulation from a German facility. It is the closest direct competitor to SyVento in Europe for end-to-end mRNA-LNP CDMO work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/syvento

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syvento BioTech